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OBJECTIVES: According to a report from the Rarer Cancers Foundation of England,
within the first six months of the launch of the Cancer Drugs Fund in England, only
£ 27,437,466 were used while the total amount allocated for the same period was
£50,000,000. This means that only a 56% of allocated funds for that period were
used. In a health system that restricts access to those oncological treatments that
have not shown to be cost-effective or have not been assessed by NICE a more
optimal use of the available funds would have been expected. In this study the
authors try to explore and determine the possible underlying reasons for the ob-
served underspent of allocated budget within the Cancer Drugs Fund in England
from October 2010 to March 2011. METHODS: Interviews were conducted across
different SHAs (Strategic Health Authorities) in England (n5) in 2011. A specific
questionnaire was designed to conduct this research RESULTS:Majority of respon-
dents mentioned delays in application for drug funding, miscalculation of expected
number of application by clinicians, among other reasons for underspent of Cancer
Drugs Fund CONCLUSIONS: SHAs should make sure that funds are properly allo-
cated and used in the benefit of patients and no application should be rejected in
the basis of an economic reason but just on pure clinical reasons
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OBJECTIVES: Analyzing the cancer incidence and TNM – classification is done by
national statistic in high spatial resolution, but no detailed data regarding pre-
existing illnesses and treatment pathways are gathered. That is why these prob-
lems are focused on using billing data from extramural and intramural anony-
mised patients datasets extended by drug prescription information. METHODS:
Starting with anonymized single person spatio-temporal hospital data including
diagnoses coded by ICD10, medical attendance data and patient identity key a
pre-selection is realized. In the next step the intramural patient history is focused
on, detecting the first indicated hospitalization. Afterwards criteria for the number
of reuptakes as well as for exclusion of cases (filtering not new diseases) are defined
based on the intramural patient history. Analyzing cancer indicated drug admin-
istration and drug prescription the year before the first hospitalization, knowledge
about risk groups is collected and evaluated. Additionally the probability of surviv-
ing regarding different treatment courses is measurable. These calculations are
done exemplary. RESULTS: Comparing the incidences calculated out of casemix
datasets for liver cancer, lung cancer and mamma carcinoma high accordance
comparing to cancer registry of Austria is observed. In case of liver cancer the
overall deviation is 14 cases per year; equal to a difference of 1.5 percent. In case of
mamma carcinoma 4882 detected new infections in control year 2007 are faced
with 4833 new cancer diseases registered by national statistics. CONCLUSIONS:
Using detailed single person spatio-longitudinal billing datasets in combination
with extended search strategies using exclusion criteria based on expert knowl-
edge as well as data structure information and modeling skills, highly reliable
datasets are edited. The analyzed background knowledge can be used in modern
dynamical simulation models producing reliable results.
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OBJECTIVES: European payer authorities reimburse the administration of antican-
cer agents for mNSCLC patients according to diverging tariffs and varying codes.
This poses the question of whether there is the need for a sensitivity analysis of
administration costs in health economic models when applied in France, Germany,
Italy, Spain, and the UK. METHODS: Two systematic literature reviews of the bib-
liographic database Medline were performed in order to identify relevant publica-
tions (of year 2000) on administration costs of chemotherapy for the treatment of
NSCLC. The review was supplemented by a search in the databases of the Cochrane
Library, EMA-EPAR, and ClinicalTrial.GOV. In addition, treatment guidelines, reim-
bursement databases, and national reimbursement tariffs were hand-searched.
Semi-structured interviews with expert oncologists were completed. Data extrac-
tion and evidence synthesis from these sources formed the basis of this evaluation.
RESULTS: Twenty-three manuscripts, 108 phase III study protocols, 6 EMA-labels,
and 12 European treatment guidelines were included in the analysis. The ten
NSCLC antineoplastic drugs mentioned in the ESMO and NCCN guidelines cover a
wide set of administration patterns with respect to 1st or 2nd line monotherapy,
combination therapy, and mono-or combination-maintenance therapy. The treat-
ment schedules vary in dose per application, composition per cycle, and number of
cycles. The main tariff for France is GHS 9606/GHM 28Z07Z (€386), for Germany
daycase DRG 71B (€720) and several separate agreements (“Onkologievereinba-
rung”) and for the UK daycase HRG SB97ZSB13Z (£399). For Italy and Spain the
actual DRG values vary tremendously, for instance in Italy for DRG410 (€310 for
Emilia Romagna vs. €40 for Basilicata), and in Spain C.6 for Galicia (€170) or 1.7.2.2
for Asturia (€149). CONCLUSIONS: The difference in treatment schedules in com-
bination with the variation in national administration tariffs shows the importance
of a sensitivity analysis when conducting a health economic analysis of NSCLC
administration costs in Europe.
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OBJECTIVES: In January 2009, the National Institute for Health and Clinical Excel-
lence (NICE) adopted an evaluation process for life-extending end-of-life treat-
ments. For eligible drugs, QALYs are weighted to favour the incremental cost-
utility ratios (ICUR). Also, patient access scheme (PAS, pricing agreements) are
sometimes established between the NHS and drug manufacturers to lower the
economic impact of costly drugs. The purpose of this study was to document the
effects of the end-of-life evaluation process (EOL) on anticancer drugs listing
recommendations. METHODS: NICE website was searched to identify published
technology appraisal guidances of anticancer drugs issued between January 2009
and May 2011. We documented EOL and PAS status, the listing recommendation
and the supporting ICURs. Positive and negative recommendations were stratified
by EOL and PAS status. RESULTS:We retrieved 32 recommendations among which
50% were approvals. The proportion of accepted drugs tends to be higher among
those evaluated with the EOL (9/16; 56%, p0,8). The ICURs of positive recommen-
dations associated with drugs not eligible or not considered for the EOL were
mostly comprised between 20,000£/QALY and 30,000£/QALY gained. On the other
hand, ratios of positive recommendations for drugs eligible to the EOL were higher
and varied from 30,350£/QALY to 54,366£/QALY gained. Among drugs evaluated
with the EOL, the proportion of accepted drugs analysed with PAS (6/9; 67%, p0,51)
tends to be higher than for drugs accepted without PAS. CONCLUSIONS: Despite
the small number of evaluations since its implementation, we observed with the
EOL a higher ICUR threshold that may have led NICE to recommend to list more
anticancer drugs that it would have been without the EOL. When the EOL was
considered, PAS also seems to have contributed to a higher rate of positive listing.
These findings have raised questions about the economic evaluation of anticancer
drugs in Canada.
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OBJECTIVES: To understand relative price differential for cancer drugs in the US
and the UK. Develop implications for pricing strategy and patient access for cancer
drugs. METHODS: Ten branded cancer drugs were selected and their prices for
similar dose and packaging were compared in the US and the UK. Prices were
analyzed for the end of 2010 and early 2011. Historical exchange rates were used to
convert British pounds to US dollars. Relative price discount was calculated for all
selected cancer drugs. KOLs and payers were interviewed to understand current
and future implications of this price differential. RESULTS: The median price dis-
count for selected ten branded cancer drugs in the UK versus the US was50%. The
range of discount for 10 branded cancer drugs was 27%-61%. The price discount for
oral small molecule drugs was higher than for biologics (55% versus 45%). Since UK
is one of the few remaining free pricing markets in Europe, other European markets
are likely to have even higher discounts relative to the prices in the United States.
Due to rising coinsurance of speciality products, US cancer patients bear signifi-
cantly higher cost than patients in the UK. KOL and payer interviews suggest US
pricing trends for cancer drugs are unlikely to be sustained at this level in the
future. CONCLUSIONS: US cancer drug prices are significantly higher than the
prices in the UK. This price differential is unlikely to be sustained in the future.
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OBJECTIVES: Objective of this study was to assess reimbursement outcomes and
patient access to oncology drugs in Croatia. National Institute of Clinical Excellence
(NICE) cancer guidelines and National Comprehensive Cancer Network (NCCN)
guidelines were used as benchmark. NICE is known for being committed to com-
plying with legal obligations on equity and human rights, conducting their work
based on identified cost effectiveness thresholds and known to be restrictive in
their recommendations. On the other hand, NCCN professional guidelines are key
international guidelines for oncology professionals which have been accepted and
followed worldwide. METHODS: Reimbursement processes, specific indications
and restrictions for 23 studied cancer drugs, ATC L01 class (antineoplastic agents)
have been analyzed and compared to UK NHS funding and reimbursement recom-
mendations given through NICE cancer guidelines as well as recommendations
given through NCCN guidelines. RESULTS: Studied cancer drugs were used for the
treatment of 14 different tumor locations: breast, colon, lung, leukemia, renal,
GIST, ovary, lymphoma, glioblastoma, prostate, liver, gastric, myeloma. Among 57
registered indications, Croatian Health Insurance Fund has in total reimbursed 43
(75%) while NICE has issued positive recommendations for only 35 (60%). On the
other hand, all investigated drugs and relevant indications except of one partially
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have been recommended by NCCN guidelines. At the same time, we identified
many instances where the recommendations given by the NCCN guidelines have
not been endorsed by HZZO. CONCLUSIONS: Considering process related incon-
sistencies and consequential differences in reimbursement outcomes and patient
access to cancer drugs in Croatia compared, there is a strong need for the expedited
implementation of transparent HTA processes for cancer drugs. Multiple technol-
ogy assessments of the main indication groups and the highest cost drivers are
highly needed to ensure the full transparency of the reimbursement system and
the equity of patients’ access to the treatment options irrespectively of the disease.
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OBJECTIVES: Determine the impact of new end of life criteria on reimbursement
decisions of cancer drugs appraised by NICE. METHODS: Review of Single and
Multiple Technology Assessments on cancer treatments appraised by NICE from
January 2009 to April 2011. RESULTS:NICE appraised 30 cancer treatments. 16 were
recommended with restrictions and 13 were not recommended. The reason for not
recommending was poor cost effectiveness (7) and lack of evidence (6). The Com-
mittee considered the impact of giving a greater weight to QALYs achieved in the
later stages of terminal diseases in nine of the positive recommended drugs. End of
life criteria were considered when the most plausible ICERs fall above the threshold
normally considered as cost-effective. End of life criteria were not taken into ac-
count when the appraised drugs had ICERS below £30,000 per QALY gained (6 cases)
or when it resulted in cost saving for the NHS. When ICERs estimates exceeded
what NICE considers a reasonable use of NHS resources for the whole population
covered by the marketing authorisation the Committee discussed whether the
magnitude of weight required for the ICER to be in a cost effective range was
acceptable in special subgroups of population. CONCLUSIONS: The discussion of
end of life criteria was straight forward when the new drug provided a marked
change in the treatment of the disease or its high price was compensated by a
patient access scheme agreement. On contrary, it was more difficult to decide
whether survival benefits offered the extension of life required in order the sup-
plementary advice to be considered. The supplementary advice facilitated the ap-
praisal process of cancer drugs however the Committee had to make judgments to
interpret the incomplete evidence in order to decide what is good for patients and
who can benefit from new cancer treatments.
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OBJECTIVES: Reducing the burden of cancer through interventions based on clin-
ical trials remains an important strategy of oncology research. Public access to
information on clinical trials increases transparency of medical research and helps
patients to find information. The aim of this study was to investigate the number of
clinical trials in oncology carried out in Greece. METHODS: We searched the EU
Clinical Trials Register website. We analyzed the trends regarding the number of
approved by the National Organization for Medicines trials in a 7-year basis. We
also examined the number of trials by the type of cancer, the Phase and the status
of the trial and the trends in funding. In our survey we included only Phase II and
Phase III interventional trials, recruiting by adults and elderly, both men and
women, between 2004-2010. RESULTS: Greece ranks 14th among EU countries for
the clinical trials conducted in oncology, as 24,29% of all clinical trials carried out in
Greece concern cancer. Since 2004, 44 Phase II and 95 Phase III trials were approved,
the majority of which were related to target therapies of breast cancer (21.73%) and
non-small cell lung cancer (21.01%). 81.88% are still ongoing trials, 6.52% have been
completed while there is no feedback about the results. Finally, in Greece the main
sponsor in clinical research is industry (88.4%) while only 11.59% is funded by
research institutes. CONCLUSIONS: Although in Greece there is significant clinical
investigation in oncology, the need for the development of a new framework as
well as a well organized network that will inform key stakeholders, reduce bureau-
cracy and increase the number of clinical trials remains and calls for international
cooperation.
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OBJECTIVES: To identify empirical threshold values for cost-effectiveness on the
basis of past decisions in Agency for Health Technology Assessment (AHTAPol) in
Poland and National Institute for Health and Clinical Excellence (NICE) in the UK for
cancer drug technologies. METHODS: Review of recommendations issued by
AHTAPol and NICE for cancer drug technologies was performed. Period under in-
vestigation was August 2007 to March 2011 for AHTAPol and March 2000 – March
2011 for NICE. To identify empirical threshold values in both agencies, a compari-
son of ICER cost/QALY and past decisions was made. RESULTS: In the studied
period AHTAPol and NICE issued, respectively, 44 and 54 recommendations for
cancer drug technologies. Negative recommendations prevailed in Poland (43%).
Most common recommendations in NICE were positive recommendations with
major restriction (39%).The most commonly used measure of cost-effectiveness in
NICE was ICER cost/QALY (41 recommendations) while in Poland it was identified
only in 16 recommendations. As a result of a comparison of ICER cost/QALY and
past decisions empirical threshold values in both agencies were not identified. In
Poland four positive recommendations with restrictions and 9 negative ones were
placed above official AHTAPol’s threshold. In the same time, only 3 positive rec-
ommendations with or without restriction were below the threshold. In NICE, 17
positive recommendations with or without restrictions and 11 negative ones were
above the official threshold value of £30,000/QALY. Below this threshold, there
were 13 positive recommendations with or without restrictions. CONCLUSIONS:
AHTAPol, as well as NICE, don’t have definite empirical cost-effectiveness thresh-
old values for cancer drug technologies. The official threshold values set in both
agencies are not respected in the case of cancer drugs. Implementation of addi-
tional guidelines for “end-of-life” treatment in NICE may have potential impact on
decisions concerning cost-effectiveness of cancer drug technologies.
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OBJECTIVES: After marketing authorization, European HTA agencies may take
HRQoL data into account to support reimbursement. We want to explore here how
HRQoL have been included into HTA process and what their impact was on reim-
bursement decisions. METHODS: Initially, we’ve analyzed French HRQoL data on
oncology drugs to assess quality, type and impact of these data on the reimburse-
ment opinions made by the French National Autority (HAS). In the second stage, we
have performed a qualitative analysis to explore the main similarities and differ-
ences across HTA bodies in assessment of HRQoL to support reimbursement.
RESULTS: First stage: since 2008, 23 files were assessed by HAS. HRQoL data were
available for 11 oncology drugs; for 3 drugs HRQoL data were not taken into account
(open trial or missing data). For 5 drugs, no difference in HRQoL (on EORTC QLQ-
C30) was observed and in 3 cases, change in HRQoL might have had an impact on
final decisions.Second stage: more and more often HRQoL data are included into
files submitted for HTA and their quality is gradually improving over time. How-
ever, confusion still remains between functional measures and HRQoL. Some
countries only consider HRQoL data from randomised clinical trials. For other
countries, data from observational studies may also be of interest to provide addi-
tional information in real conditions of use. In addition, many countries consider
utility measures as one of HRQoL. In all cases, HRQoL remains a secondary end-
point in relative effectiveness assessment (REA) process. CONCLUSIONS: In Eu-
rope, the impact of HRQoL on reimbursement decisions could be enhanced if the
quality of data increases. Our analysis confirms the interest of the ongoing work on
the EUnetHTA guideline that should help assessors of European HTA agencies deal
with HRQoL and contribute to the harmonization of HRQoL definitions and use
across agencies.
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OBJECTIVES: Although prostate-specific antigen (PSA) screening is conducted
worldwide, its effectiveness in reducing mortality from prostate cancer has re-
mained controversial. In March 2009, intermediate results from the European Ran-
domized Study of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung,
Colorectal and Ovarian (PLCO) Cancer Screening Trial were released. However, the
results of the two studies were inconsistent: the PLCO trial demonstrated no ben-
efits to screening, whereas the ERSPC study reported a 20% reduction in prostate
cancer mortality. We found and compared the assessment of the two RCTs in
guidelines, evidence reports and statements. METHODS: A search was performed
from March 2009 to May 2011 using MEDLINE, the Guideline International Network
library and the National Guidelines Clearinghouse to identify guidelines, evidence
reports and statements which have evaluated the two RCTs. Additional reports
recommended by experts were also included as needed. The changes in the revised
guidelines, evidence reports and statements were compared. RESULTS: Four
guidelines, two evidence reports and one statement matching our criteria were
found, but none contained any change in basic recommendation for PSA screening.
In addition, the American Society of Clinical Oncology evaluated the results of the
two studies in their review for major research in 2009. Although the American
Urological Association recommended PSA screening for men 40 years of age and
over, in other guidelines, PSA screening was not recommended for asymptomatic
persons. Most of the US reports were for opportunistic screening and pointed out
the necessity of shared decision-making for PSA screening. The European Urolog-
ical Association and the UK-NHS Cancer Screening Committee did not recommend
PSA for population-based screening. In contrast, the Japanese Urological Associa-
tion strongly recommended PSA screening in communities. CONCLUSIONS: Even
after the releases of two RCTs results, most reports have not revised their assess-
ment of PSA screening.
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